CoChat

Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events

Basch, E., Bennett, A., Pietanza, M. C. · 2011 · JNCI Journal of the National Cancer Institute
Cited by 109

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Abundant research has now demonstrated that patient and clinician reports of symptoms—and particularly symptomatic toxicities (ie, adverse events) during cancer treatment—provide discrepant yet complementary data ( 1–3 ). How can this be? Can’t only the patient or the clinician be “right”? The more patient-centered among us might state that the patient is always right by definition because nobody (not even the most sensitive clinician) can truly know another person's subjective experience. But the more traditional among us might assert that clinicians should be considered right because they have an “objective” perspective based on experience and training, which prevents them from exaggerating or understating what they observe. In fact, it appears that both the patient and clinician provide information of value, which when combined provides a more accurate understanding of the patient’s symptoms. This finding is good news for those of us who are interested in improving the measurement of symptoms in clinical trials and practice. The optimistic among us might state that all we need to do now is figure out how to operationalize this approach. The current standard mechanism for reporting toxicities in cancer research is clinician-only reporting using items from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) ( 4 ). Any cancer clinician is familiar with these approximately 800 items—about 10% of which represent symptoms such as nausea, fatigue, or sensory neuropathy—and all of which are currently reported by clinicians only, with no explicit mechanism for patient direct reporting. The article by Quinten et al. ( 5 ) in this issue of the Journal demonstrates that adding information gathered directly from study participants via patient-reported outcome (PRO) measures improves the predictive accuracy of clinician CTCAE reporting (eg, raising the adjusted C-index from 0.63 to 0.67 for fatigue and from 0.62 to 0.65 for nausea, which represents a substantial improvement) ( 6 ). This important finding adds to previous work supporting the added value of PRO measurements to existing mechanisms for clinician toxicity reporting. Previously, we reported in the Journal ( 2 ) that although clinicians are able to predict survival well, patient reporting of symptomatic toxicities better reflects the patient's underlying health state and functional status. Moreover, patient reporting appears to detect potentially serious adverse event symptoms earlier than clinician reporting. This phenomenon was notably demonstrated by the timing and cumulative incidence of patient vs clinican reporting of severe diarrhea in the IFL (irinotecan/fluorouracil/leucovorin) arm of NCI intergroup trial N9741 ( 7 ), in which an abundance of life-threatening gastrointestinal serious adverse events was ultimately detected ( 8 ). Therefore, availability of PRO data not only enhances the accuracy of clinician CTCAE reports but also may improve safety. So, operationally how might this work? There are three potential approaches: 1) “Independent reporting,” in which patient and clinician toxicity data are collected, analyzed, and reported completely separately from each other; 2) “Merged reporting,” in which patient and clinician data are collected separately and then merged analytically into a single metric; and 3) “Collaborative reporting,” in which patients directly report symptomatic toxicity information, which is then provided to clinicians to inform their CTCAE reporting. Of these three approaches, we favor the third, collaborative reporting. This approach provides clinicians with valuable information about the patient experience immediately to inform not only their required research reporting but to support their ongoing management of symptoms and communication with patients. There is ongoing research to determine which approach is most informative (described below). Moreover, the third approach capitalizes on knowledge that the patient and clinician have of each other rather than relying on an artificial calculation to merge their perspectives. (There are also existing models of independent reporting by professionals vs consumers that are well accepted, such as commercial websites that post the scores of professional reviewers side-by-side with aggregated consumer reviews of anything from electronics to movies to cars to hotels.) A collaborative reporting approach was recently integrated into a phase II clinical trial of paclitaxel, pemetrexed, and bevacizumab in patients with advanced non–small cell lung cancer at Memorial Sloan-Kettering Cancer Center (E. Basch, M.C. Pietanza, and M. G. Kris, unpublished data). At each visit, via wireless tablet computers, 44 patients self-reported 13 CTCAE symptoms (alopecia, anorexia, cough, dyspnea, epiphora, epistaxis, fatigue, hoarseness, mucositis, myalgia, nausea, pain, sensory neuropathy) using a previously developed questionnaire (2). This information was transmit

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djr493

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 109

Metadata

Authors
Basch, E., Bennett, A., & Pietanza, M. C.
Venue
JNCI Journal of the National Cancer Institute
Published
2011-12-07
Volume
103
Issue
24
Pages
1808-1810
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2108285925
Cited by
109
References
1
FWCI
3.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events. https://app.cochat.ai/papers/10.1093/jnci/djr493
The paper
Basch, E., Bennett, A., & Pietanza, M. C. (2011). Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr493

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.